Sinopharm Subsidiary Posts 2025 Revenue Growth Amid Flat Earnings and Stronger Cash Flow

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Sinopharm Group Co ( (HK:1099) ) has issued an update.

Sinopharm Group has disclosed the 2025 audited financial results of its Shanghai-listed subsidiary China National Medicines Corporation, showing modest top-line growth but largely flat profitability. Revenue rose 3.7% year on year to RMB 52.47 billion, while net profit attributable to shareholders slipped 0.18% to RMB 1.997 billion, and earnings per share were essentially unchanged.

Despite the slight earnings decline, SINOPHARM CNCM improved its cash generation, with net operating cash flow up 20.88% versus 2024 and net assets attributable to shareholders increasing 8.27%. The weighted average return on net assets fell by nearly one percentage point, indicating some margin pressure even as total assets expanded 5.03%, suggesting steady but moderating profitability for stakeholders in a growing asset base.

The most recent analyst rating on (HK:1099) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.

More about Sinopharm Group Co

Sinopharm Group Co. is a major Chinese pharmaceutical and healthcare company, with its subsidiary China National Medicines Corporation Ltd. (SINOPHARM CNCM) engaged in the distribution and trade of medicines and related healthcare products. The subsidiary’s A shares are listed on the Shanghai Stock Exchange, positioning it as a significant player in China’s pharmaceutical supply chain.

Average Trading Volume: 5,305,954

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$65.72B

For an in-depth examination of 1099 stock, go to TipRanks’ Overview page.